Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]PI-2620 PET Imaging in Alzheimer's Disease and Progressive Supranuclear Palsy
NCT04715750Phase 1Completed
- Sponsor
- Life Molecular Imaging
- Start
- Nov 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-PI-2620 in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), sponsored by Life Molecular Imaging. Primary endpoint: Comparability of visual assessment of PI-2620 tau PET images obtained after injection of high specific activity and low specific activity. Started Nov 2020; status: completed.
02
Drugs
18F-PI-2620
03
Conditions
Alzheimer's disease (AD)progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT04715750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715750.